TABLE 4

Univariable analysis of the association between potential predictor variables and microbiological eradication in patients with MRSA bacteremia

VariablebValue for the variablea
OR95% CIP value
Treatment group (Combo vs VAN alone)5.151.21–29.70.026
Age (yr)0.990.95–1.040.719
LOS (days)1.040.99–1.140.101
Vancomycin serum level (mg/liter)c0.970.93–1.010.136
Cancer1.240.24–12.410.816
Hemodialysis0.070.01–0.33<0.001
Immunosuppression3.510.39–465.030.317
Injection drug use4.960.56–654.410.178
MRSA colonization0.760.17–4.440.733
Endocarditis1.020.24–5.880.985
Osteomyelitis4.580.52–604.590.206
ICU admission0.790.19–3.670.753
Ventilator use1.460.29–14.560.676
Pitt bacteremia score of ≥41.070.82–1.690.653
MRSA strain (USA300 vs USA100)2.520.62–11.670.197
agr functionality1.080.18–4.770.920
  • a The odds ratio (OR) and 95% confidence interval were derived using Firth's penalized maximum likelihood bias reduction approach to logistic regression.

  • b LOS, length of stay; ICU, intensive care unit.

  • c One patient in each treatment group did not have a vancomycin serum level documented in the electronic medical record. Both patients experienced microbiological eradication.